Historical biib News Stories
Biogen Slides: 3-Day Drop, Alzheimer Lead Grows Up
Biogen (BIIB) slipped for a third straight day amid light volume even as competitor setbacks in Alzheimer’s research reinforced Biogen’s Leqembi positioning. Recent coverage shows a near-term pullback in the shares, limited reaction across biotech to a Fed rate cut, and concrete competitive developments — all tangible drivers for BIIB investors to evaluate.
Biogen Surges After Dayra Deal, Leqembi sBLA Push.
Biogen (BIIB) climbed after a research collaboration with Dayra Therapeutics and a rolling sBLA submission for Leqembi IQLIK. These concrete developments—$50M upfront, subcutaneous dosing pathway, and recent stock moves—offer clear near-term catalysts.
Biogen Rally: Dayra Pact, Leqembi, Q3 Beat, NovoRx
Biogen (BIIB) climbed after a strategic Dayra Therapeutics collaboration, a rival Alzheimer’s setback from Novo Nordisk, and a stronger-than-expected Q3. Upcoming CTAD presentations and real-world Leqembi data offer additional near-term catalysts.
Biogen Strengthens With ThecaFlex Deal, CHMP Win!!
Biogen (BIIB) saw concrete catalysts last week: completing the ThecaFlex acquisition and securing a positive CHMP opinion for high‑dose nusinersen. Stock moves and analyst updates reflect renewed investor focus on delivery tech and regulatory progress.
Biogen's Leqembi Win, Vanqua Deal, Q3 Headwinds Up
Biogen (BIIB) saw three clear catalysts this week: Health Canada approved lecanemab (LEQEMBI®) for early Alzheimer’s, Biogen inked an exclusive deal with Vanqua Bio for a preclinical oral C5aR1 antagonist, and Q3 results prompted a trimmed full-year earnings outlook. These developments expand commercial reach and pipeline diversity but introduce near-term financial pressure that investors should weigh.
Biogen Beats Q3 but Cuts Guidance - Stock Rebounds
Biogen reported better-than-expected Q3 results but trimmed full-year guidance, announced a strategic licensing deal, and saw analyst upgrades—driving a rebound in BIIB shares amid mixed near-term signals.